

**EPHMRA**  
**ANATOMICAL CLASSIFICATION**  
**GUIDELINES 2026**

**Section A**

**Changed Classes/Guidelines: Changes Highlighted**

**Final Version**

**Date of issue: 16<sup>th</sup> December 2025**

<b>A5</b>	<b>BILIARY TRACT AND LIVER DISORDER PRODUCTS</b>	r2023
<b>A5A</b>	<b>BILIARY TRACT DISORDER PRODUCTS</b>	r2023
A5A1	<b>Cholagogues</b>  Includes products, plain and in combination, indicated as choleretics and cholekinetics.	r2023
A5A2	<b>Bile stone therapy</b>  Includes products indicated for biliary conditions such as stone dissolvers eg chenodesoxycholic acid, ursodesoxycholic acid. Products containing ursodesoxycholic acid for primary biliary cholangitis are classified here.	r2018
A5A9	<b>Biliary tract disorder products, other</b>  Includes products containing obeticholic acid for primary biliary cholangitis.	r2023
<b>A5B</b>	<b>LIVER DISORDER PRODUCTS, HEPATIC PROTECTORS AND LIPOTROPICS</b>  Includes products for liver disorders such as <u>NASH</u> <u>(metabnon-alcoholic dysfunction-associated</u> <u>steatohepatitis</u> <u>(MASH)</u> , hepatic protectors and combinations, but excludes liver extracts indicated for the treatment of anaemia, which are classified in B3B.	r202 <u>63</u>
<b>A5C</b>	<b>CHOLAGOGUE/LIPOTROPIC COMBINATIONS</b>	

A11	<p><b>VITAMINS</b></p> <p><u>Multivitamins are combinations of three or more vitamins and must contain vitamin A and/or vitamin D.</u></p> <p><u>Multivitamins for parenteral infusion are classified in K4D (less than 100ml).</u></p> <p>Products containing vitamins which are specifically for eye conditions are classified in S1M.</p> <p><u>Multivitamins for parenteral infusion are classified in K4D (less than 100ml).</u></p>	r2026 R2005
A11A	<b>MULTIVITAMINS WITH MINERALS</b>	r2017
	Includes products containing more than two vitamins in combination (and not specified elsewhere) with one or more minerals, eg calcium, potassium, magnesium, iron, copper, manganese and zinc etc. Potassium and magnesium aspartate are not considered as minerals (see A12 and C6X). Excluded are all oral preparations containing procaine where procaine is one of the major components (see A13A1).	
A11A1	<b>Prenatal</b>	r2023
	Includes those products specifically indicated for vitamin supplementation during pre-conception, pregnancy or lactation (eg containing fluoride as mineral).	
A11A2	<b>Paediatric</b>	
	Includes products with halibut liver oil or vitamin D which are indicated only for paediatric conditions. Products with malt extracts are classified in A13A.	
A11A3	<b>Geriatric</b>	
	Includes vitamin preparations with hormones for geriatric patients. The term "ger" often forms part of the name of products in this group (see also A14A2).	
A11A4	<b>Other multivitamins with minerals</b>	
	Includes all other multivitamin products not specified in A11A1, A11A2 or A11A3. Calcium-containing products promoted for osteoporosis or calcium deficiency are classified in A12A. Vitamin C combinations, eg promoted for hypovitaminosis C, are classified in A11G2. When in doubt the calcium component takes precedence over the other ingredients. Products based on lecithin or glutamic acid used as tonics are classified in A13A.	

A11E2	<b>Vitamin B complex with vitamin C</b>  Includes vitamin B complex combinations with vitamin C only, except when they contain other drugs as well (see A11E3).	R2003
A11E3	<b>Vitamin B complex with other drugs</b>  Includes products containing vitamin B complex and other components, with or without vitamin C.	R1998
A11F	<b>PLAIN VITAMIN B12</b>  This group contains plain vitamin B12 (cyanocobalamin, hydroxocobalamin) products, with or without lidocaine. Combinations with other substances are classified in either A11A, A11B, A11D, A11E, A11X9, B3B or B3X.	R2003
A11G	<b>VITAMIN C, INCLUDING COMBINATIONS WITH MINERALS</b>	
A11G1	<b>Plain vitamin C (including vitamin C salts)</b>	
A11G2	<b>Vitamin C combinations</b>  Products of this group include vitamin C with other components, but products with calcium salts for the therapy of calcium deficiency or osteoporosis are classified in A12A. When in doubt, the calcium component takes precedence over the other ingredients.  <u>Specific vitamin C combinations are classified as follows; with vitamin B1 in A11D9; with vitamin B complex in A11E2; with vitamin A only, or vitamin D only, are classified in A11X9. Multivitamin combinations containing vitamin C are classified in A11A or A11B.</u>  <u>Combinations of vitamin C with other vitamins are classified in A11A, A11B, A11D9, A11E2, A11E3 and A11X9. If combined For other vitamin C combinations with only one vitamin, and possibly other substances, A11X9 is appropriate.</u>	<u>rR202</u> <u>603</u>
A11H	Out of use; can be reused.	
A11J	Out of use; can be reused from 2005.	D2002
A11X	<b>OTHER VITAMINS</b>	I2002
A11X1	<b>Nicotinamide (vitamin B3), plain</b>  Includes products containing nicotinamide (vitamin PP).	R2003
A11X2	<b>Vitamin B6 (pyridoxine), plain</b>  Pyrithioxine products are included in N6D.	I2002

A11X3 | **Vitamin E, plain**

Combinations with vitamin A are in A11C1. Vitamin E products with wheatgerm are classified here.

I2002

<b>B6</b>	<b>ALL OTHER HAEMATOLOGICAL AGENTS</b>	R1996
<b>B6A</b>	Out of use; can be reused from 1999.	D1996
<b>B6B</b>	<b>HYALURONIDASE</b>	
<b>B6C</b>	Out of use	D2020
<b>B6D</b>	<b>HEREDITARY ANGIOEDEMA PRODUCTS</b>	I2015
	Includes products containing eg C1 inhibitor/conestat alfa, ecallantide, icatibant, etc when indicated for hereditary angioedema.	
<b>B6X</b>	<b>OTHER HAEMATOLOGICAL AGENTS</b>	r202 <del>65</del>
	Includes haemins. Excluded are those preparations used in the treatment of veins and haemorrhoids (C5) and preparations for dermatological use (D3A).	
	<del>Products containing fostamatinib or oprelvekin for the prevention of severe thrombocytopenia are classified in B2E9.</del>	
	<del>Products containing complement inhibitors: for paroxysmal nocturnal haemoglobinuria (PNH) and/or atypical haemolytic uraemic syndrome (aHUS) only are classified here; for kidney conditions only, eg IgA nephropathy, are classified in G4X; for multiple conditions are classified in L4X.</del>	
	Products for sickle cell disease (SCD), including those for haemolytic anaemia associated with SCD, (eg voxelotor), <u>and those for transfusion-dependent β-thalassaemia and SCD (eg exagamglogene autotemcel)</u> are classified here.	
	<del>Products containing complement inhibitors: for paroxysmal nocturnal haemoglobinuria (PNH) and/or atypical haemolytic uraemic syndrome (aHUS) only are classified here; for kidney conditions only, eg IgA nephropathy, are classified in G4X; for multiple conditions are classified in L4X.</del>	
	<del>Products containing fostamatinib or oprelvekin for the prevention of severe thrombocytopenia are classified in B2E9.</del>	
	Products for haemolysis in cold agglutinin disease, and pyruvate kinase deficiency (PKD) are classified in B3X.	

<b>C1D</b>	<b>CORONARY THERAPY EXCLUDING CALCIUM ANTAGONISTS AND NITRITES</b>	R2007
	<p>This group includes all other products indicated for coronary insufficiency and angina pectoris. It includes benziodarone, capopenic acid, carbocromen, cinepazet, cinepazic acid, cloridarol, dilazep, dipyridamole, efloxate, etafenone, fenalcomine, flosequinan, hexobendine, imolamine, ivabradine, medibazine, molsidomine, oxyfedrin, trimetazidine, visnadine. Combinations with nitrates are included in C1E and with beta-blockers are included in C7B.</p>	
<b>C1E</b>	<b>NITRITES AND NITRATES</b>	
	<p>This group includes all nitrates and analogous products and combinations if they are indicated for angina pectoris. Combinations of nitrates with cardiac glycosides are classified in C1A2 and combinations with beta-blockers in C7B.</p>	
<b>C1F</b>	<b>POSITIVE INOTROPIC AGENTS</b>	R1994
	<p>This group includes substances such as amrinone, milrinone, fenoximone, piroximone, xamoterol.</p>	
<b>C1X</b>	<b>ALL OTHER CARDIAC PREPARATIONS</b>	r202 <sup>64</sup>
	<p>This group includes substances such as alprostadil, crateagus glycosides, creatinolphosphate, phosphocreatinine, levocarnitine and ubidecarenone. Combination products are only classified in this group if they contain a substance which is not in the C group.</p> <p>Products containing alprostadil for peripheral arterial occlusive disease only are classified in C4A1. Products containing alprostadil for erectile dysfunction only are classified in G4E9. Products containing alprostadil for patent ductus arteriosus only or for multiple indications are classified here.</p> <p>Products containing tafamidis for transthyretin amyloid polyneuropathy (TAP) only are classified in N7X. Products containing tafamidis for transthyretin amyloid cardiomyopathy (TAC) only are classified here. Products containing tafamidis for both TAP and TAC are classified in N7X.</p> <p>Products containing mavacamten for hypertrophic cardiomyopathy are classified here.</p> <p><u>Products used to treat pericardial disease (eg goflikcept for idiopathic recurrent pericarditis) are classified here.</u></p>	

<b>D2</b>	<b>EMOLLIENTS, PROTECTIVES</b>	
<b>D2A</b>	<p><b>EMOLLIENTS, PROTECTIVES</b></p> <p>Includes skincare products and emollients (with or without active therapeutic agents), protectives, suntan irradiation preparations, etc. Products containing afamelanotide for erythropoietic protoporphyria (EPP) are classified here.</p> <p><u>Products containing sofpironium bromide for hyperhidrosis are classified here.</u>  <del>This class also includes D-drying powders for hyperhidrosis are also classified here.</del></p> <p><u>This class also includes and</u> wound coverings containing emollients. Other wound coverings are classified according to any ingredients they contain eg D3A, D6A, D8A.</p>	r20216

<b>D3</b>	<b>WOUND HEALING AGENTS</b>	
<b>D3A</b>	<b>WOUND HEALING AGENTS</b>	R2002
D3A1	<b>Skin/dermal/epidermal/equivalents</b>  Includes bioengineered and living human skin equivalents, and also skin growth factors	R2006
D3A9	<b>All other wound healing agents</b>  Includes topical preparations for open wounds, ulcers, etc. Wound healing topical vitamins and topical anabolic steroids should be included in this group when they cannot be classified satisfactorily elsewhere. Combinations of enzymes with anti-infectives used for wound healing are classified here. This group also includes skin regeneratives and stimulants, topical extracts, eg of camomile, unspecified suspensions and topical preparations for prophylaxis and therapy of mastitis. Topical oestrogens when used for gynaecological purposes are classified in G2F. Topical haemostyptics including those for dental use are classified here. Antibiotic-containing collagen implants (eg sponges) are classified here.  Products containing diperoxochloric acid for the treatment of diabetic foot ulcer are classified here.  <u>Products containing beremagene geperpavec for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) are classified here.</u>	r202 <sup>65</sup>

[<](#)

D5X	<p><b>OTHER NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS</b></p> <p>Includes nonsteroidal products for inflammatory skin disorders which are not indicated for psoriasis. Specific topical immunomodulators for dermatitis are classified here.</p> <p><u><a href="#">Products containing nemolizumab for pruritus associated with atopic dermatitis are classified here.</a></u></p> <p><u><a href="#">Products containing remibrutinib for chronic spontaneous urticaria (CSU) are classified here.</a></u></p> <p>Products containing ingenol mebutate or diclofenac gel that are indicated for actinic keratosis are classified here. <u><a href="#">Products containing topical fluorouracil for actinic keratosis are classified in L1B.</a></u> Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified in L1X8. <u><a href="#">Products containing topical fluorouracil for actinic keratosis are classified in L1B.</a></u></p> <p>Products containing dupilumab for atopic dermatitis only are classified here. Products containing dupilumab for both atopic dermatitis and asthma are classified in L4C.</p> <p><u><a href="#">Products containing nemolizumab for pruritus associated with atopic dermatitis are classified here.</a></u></p> <p><u><a href="#">Products containing ligelizumab for urticaria are classified here.</a></u></p> <p>Products containing JAK inhibitors, eg ruxolitinib, for atopic dermatitis and/or other inflammatory skin disorders, eg alopecia areata, vitiligo, etc, are classified here. Products containing JAK inhibitors for inflammatory skin disorders and other non-dermatological conditions are classified in L4D.</p>	r202 <u>64</u>
-----	---	----------------

<b>G2</b>	<b>OTHER GYNAECOLOGICALS</b>	
<b>G2A</b>	<b>UTEROTONIC PRODUCTS</b>	r2019
	Includes products used to induce labour (including delivery of placenta) and/or to reduce postpartum haemorrhage. Includes oxytocics and prostaglandins E1 and E2, and products used for cervical dilatation.	
<b>G2B</b>	<b>TOPICAL CONTRACEPTIVES</b>	
<b>G2C</b>	Out of use; can be reused from 2000.	D1997
<b>G2D</b>	<b>PROLACTIN INHIBITORS</b>	r202 <sup>65</sup>
	This group includes products used as prolactin inhibitors and containing bromocriptine, cabergoline, pergolide, quinagolide, terguride etc.	
	Products containing bromocriptine: for multiple conditions are classified here: for diabetes mellitus <del>are</del> —only <u>are</u> classified in A10X9: for acromegaly only are classified in H1C2: for Parkinson's disease only are classified in N4A. <del>In Japan, all bromocriptine is classified in N4A.</del>	
<b>G2E</b>	<b>LABOUR INHIBITORS</b>	I1997
	This group includes products acting as labour inhibitors eg ritodrine.	
<b>G2F</b>	<b>TOPICAL SEX HORMONES</b>	r2021
	This group includes all topical hormones and/or steroids indicated for gynaecological conditions. Transdermal patches and vaginal formulations containing oestrogens and intended for a systemic effect are classified in G3C.	
	Products containing progesterone in topical form (such as gel) for relief of breast pain are classified here.	
<b>G2X</b>	<b>OTHER GYNAECOLOGICAL PRODUCTS</b>	I1997
<b>G2X1</b>	<b>Gynaecological antispasmodics</b>	I1997
	This group includes oral analgesics and antispasmodics indicated exclusively for dysmenorrhoea.	

G4X	<p><b>ALL OTHER UROLOGICAL PRODUCTS</b></p> <p>Includes products containing local anaesthetics used specifically for premature ejaculation.</p> <p>Products for erectile dysfunction are classified in G4E. Products for both erectile dysfunction and other urological conditions are also classified in G4E. Products for improving general sexual performance (not specifically erectile dysfunction) are classified here.</p> <p>Products containing <u>sibemprelimab</u> or sparsentan for kidney conditions, eg IgA nephropathy, are classified here.</p> <p>Products containing oral budesonide for treatment of IgA nephropathy only are classified here.</p> <p>Products containing complement inhibitors: for kidney conditions only, eg IgA nephropathy, are classified here; for paroxysmal nocturnal haemoglobinuria (PNH) only are classified in B6X; for multiple conditions are classified in L4X.</p> <p>Products containing lumasiran for primary hyperoxaluria type 1 are classified here.</p> <p>Products containing voclosporin for lupus nephritis are classified here.</p>	r20265
-----	---	--------

J5B6	<p><b>Coronavirus antivirals</b></p> <p>Includes products containing bamlanivimab, casirivimab, etesevimab, favipiravir, imdevimab, molnupiravir, sotrovimab, regdanvimab, remdesivir, etc, for treatment of COVID-19.</p> <p><del>Products containing favipiravir for influenza only are classified in J5B4 (influenza antivirals).</del>—Products containing favipiravir for both influenza and COVID-19 are classified here. <u><a href="#">Products containing favipiravir for influenza only are classified in J5B4 (influenza antivirals).</a></u></p> <p><u><a href="#">Monoclonal antibodies for prevention/post-exposure prophylaxis, and for both prevention/post-exposure prophylaxis and treatment of COVID-19 are classified in J6H7.</a></u></p> <p><u><a href="#">Vaccines for coronavirus are classified in J7E6.</a></u></p> <p>Products containing immunosuppressants that have been used in COVID-19 are classified elsewhere, for example, levilimab is in L4C. Dexamethasone (has been used in COVID-19) is also classified elsewhere in the appropriate hormone class.</p> <p><del>Vaccines for coronavirus are classified in J7E6.</del></p>	r202 <sup>63</sup>
J5B9	<p><b>Antivirals, others</b></p> <p>Includes products containing lysozyme for viral infections.</p> <p>Products containing favipiravir for both influenza and severe fever with thrombocytopenia syndrome (SFTS) are classified in J5B4.</p>	r2025

<b>L</b>	<b>ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</b>	R1994
<b>L1</b>	<b>ANTINEOPLASTICS</b>  Includes all preparations mainly indicated for the treatment of cancers and all packs specifically produced for use in anticancer therapy eg special anticancer packs of antibiotics. The definition of neoplasms includes both malignant and benign conditions.  <u>Immunosuppressants used to treat cancer are classified in the appropriate antineoplastic class. For example, nogapendekin alfa inbakicept for bladder cancer is classified in L1X9</u>	r202 <sup>64</sup>
<b>L1A</b>	<b>ALKYLATING AGENTS</b>  Includes nitrogen mustard analogues (eg chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, prednimustine, trofosfamide), ethylene imines (eg altretamine (hexamethylmelamine), carboquone, thiotepa, triaziquone), nitrosoureas (eg bendamustine, carmustine, fotemustine, lomustine, semustine, streptozocin), alkyl sulfonates (eg busulfan, mannosulfan, mitolactol, treosulfan), triazenes and analogues. Dacarbazine is classified in this group.	R2003
<b>L1B</b>	<b>ANTIMETABOLITES</b>  Includes folic acid analogues (eg methotrexate), pyrimidine analogues (eg capecitabine, carmofur, cytarabine, fluorouracil, tegafur) and purine analogues (eg fludarabine, mercaptopurine, tioguanine).  Methotrexate can also be classified in M1C for rheumatic conditions or in D for dermatological conditions.  Products containing topical fluorouracil for actinic keratosis are classified here.	r2016
<b>L1C</b>	<b>PLANT-BASED ANTINEOPLASTICS</b>  Includes products that contain plant-derived alkaloids, terpenes, lignans etc, or their derivatives/analogues.  Combination products containing substances from two fourth level classes of L1C are classified in the higher level class, eg a combination of a camptothecin with a podophyllotoxin is classified in L1C3.	R2016
<b>L1C1</b>	<b>Vinca alkaloid antineoplastics</b>  Includes products containing alkaloids (or their derivatives/analogues) that are derived from <i>Cantharanthus roseus</i> (Madagascan periwinkle), eg vinblastine, vincristine, vindesine, vinflunine, vinorelbine, etc.	I2016
<b>L1C2</b>	<b>Taxane antineoplastics</b>  Includes products containing diterpenes (or their derivatives/analogues) that are derived from species of <i>Taxus</i> (yew), eg cabazitaxel, docetaxel, paclitaxel, etc.	I2016



L1G9	<p><b>Monoclonal antibody antineoplastics, other</b></p> <p>Includes antibodies with other targets including other CD targets, CTLA-4 (ipilimumab), etc. Products containing PD-1/CTLA-4 bispecific antibody antineoplastics, eg cadonilimab, are classified in L1G5. Products containing bispecific antibodies are classified in the appropriate fourth level, where a target class is available. If there is not a class for either target, the product is classified here. If there is a separate class for each target, the product is classified here.</p> <p>Includes antibody drug conjugates (ADCs) if not classified with the target class (brentuximab vedotin, <u>datopotamab deruxtecan</u>, gemtuzumab ozogamicin, inotuzumab ozogamicin).</p> <p>Includes radio-labelled antibodies (ibritumomab tiuxetan, tositumomab iodine-131).</p> <p>Includes alemtuzumab, blinatumomab, brentuximab vedotin, catumaxomab, daratumumab, dinutuximab, elotuzumab, gemtuzumab ozogamicin, ibritumomab tiuxetan, inotuzumab ozogamicin, ipilimumab, mogamulizumab, olaratumab, racotumomab, rovalpituzumab tesirine, sabatolimab, siltuximab, tositumomab, tositumomab iodine-131, etc.</p> <p>Includes products containing a combination of nivolumab with relatlimab. Products containing nivolumab alone are classified in L1G5. Products containing a combination of nivolumab with prolgolimab are classified in L1G5.</p> <p>Products containing alemtuzumab and indicated for cancer only are classified here. Products containing alemtuzumab and indicated for multiple sclerosis are classified in N7A.</p>	r20265
L1H	<b>PROTEIN KINASE INHIBITOR ANTINEOPLASTICS</b>	R2019
L1H1	<b>Protein kinase inhibitor antineoplastics, BCR-ABL</b>	I2019
L1H2	<p>Includes products containing bosutinib, dasatinib, imatinib, nilotinib, ponatinib, radotinib, etc.</p> <p><b>Protein kinase inhibitor antineoplastics, EGFR</b></p> <p>Includes products containing afatinib, dacomitinib, erlotinib, gefitinib, icotinib, olmutinib, osimertinib, varlitinib, etc.</p>	I2019

L1H3	<b>Protein kinase inhibitor antineoplastics, ALK</b>  Includes products containing alectinib, brigatinib, ceritinib, crizotinib, lorlatinib, etc.	I2019
L1H4	<b>Protein kinase inhibitor antineoplastics, BRAF/MEK</b>  Includes products containing binimetinib, cobimetinib, dabrafenib, encorafenib, selumetinib, trametinib, vemurafenib, etc.  <u><a href="#">Products containing avutometinib in combination with defactinib are classified here.</a></u>	I2026 19
L1H5	<b>Protein kinase inhibitor antineoplastics, CDK 4/6</b>  Includes products containing abemaciclib, palbociclib, ribociclib, etc. Products containing both ribociclib and letrozole are classified here.	I2019
L1H6	<b>Protein kinase inhibitor antineoplastics, BTK</b>  Includes products containing acalabrutinib, ibrutinib, tirabrutinib, zanubrutinib, etc.	I2021
L1H7	<b>Protein kinase inhibitor antineoplastics, JAK</b>  Includes products containing fedratinib, momelotinib, pacritinib, ruxolitinib, etc that are primarily for cancer.  Products containing JAK inhibitors are classified in A7 if only for gastro-intestinal conditions, in D5 if only for skin conditions (eg topical forms of ruxolitinib for atopic dermatitis), and in M1 if only for musculoskeletal conditions.  Products containing JAK inhibitors to treat multiple immune conditions are classified in L4D.	I2024

L1H9	<p><b>Protein kinase inhibitor antineoplastics, other</b></p> <p>Includes all other protein kinase inhibitor antineoplastics, for example those inhibiting HER-2 etc. PI3K inhibitors are included even though they are lipid kinase inhibitors and not strictly protein kinase inhibitors.</p> <p>Includes axitinib, cabozantinib, erdafitinib, everolimus, idelalisib, lapatinib, lenvatinib, midostaurin, neratinib, <u>nintedanib</u>, pazopanib, regorafenib, rivoceranib (apatinib), sorafenib, sunitinib, temsirolimus, tivozanib, vandetanib, <u>vimseltinib</u>, <u>zongertinib</u> etc.</p> <p>Products containing multi-kinase inhibitors, eg umbralisib etc, are classified here.</p> <p>Products containing nintedanib for idiopathic pulmonary fibrosis only are classified in R7D. Products containing nintedanib for cancer only are classified here. Products containing nintedanib for both cancer and idiopathic pulmonary fibrosis are classified in R7D.</p> <p>Products containing alpelisib for PIK3CA-related overgrowth spectrum (PROS) are classified here.</p> <p>Products containing KRAS inhibitors, eg adagrasib, sotorasib, etc, for cancer are classified in L1X9.</p>	r202 <u>65</u>
------	--	----------------

L1X8	<p><b>Photosensitisers for cancer therapy</b></p> <p>Includes products containing photosensitisers for use in cancer therapy, eg aminolaevulinic acid, methyl aminolaevulinate, methoxsalen, porfimer, talaporfin, temoporfin, etc.</p> <p>Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified here. Products containing aminolaevulinic acid for use in diagnostic procedures are classified in T1X.</p> <p>Products containing methoxsalen for other skin conditions such as psoriasis or vitiligo are classified in the appropriate D classes.</p> <p>Products containing verteporfin for macular degeneration are classified in S1P.</p>	r2023
L1X9	<p><b>All other antineoplastics</b></p> <p>Includes amsacrine, enzymes, estramustine, gallium nitrate, methylhydralazine, mitotane, pentostatin, procarbazine, substituted urea, tasonermin, vosaroxin. Also includes celecoxib for familial adenomatous polyposis (FAP).</p> <p>Includes products containing cancer gene therapies eg nadofaragene firadenovect, talimogene laherparepvec, etc.</p> <p>Products containing afibbercept for cancer are classified here. Products containing afibbercept for macular degeneration are classified in S1P.</p> <p>Products containing BCG vaccine for cancer are classified here; those for general immunostimulation are classified in L3A9. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6.</p> <p>Products containing miltefosine for skin metastases of breast cancer are classified here. Products containing miltefosine for leishmaniasis are classified in P1G.</p> <p>Products containing interferons, eg ropeginterferon alfa 2b, for cancer only are classified here.</p> <p>Products containing tabletecleucel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+PTLD) are classified here.</p> <p>Products containing antineoplastic, non-transformed cell therapies, eg lifileucel, are classified here.</p> <p>Products containing KRAS inhibitors, eg adagrasib, sotorasib, etc, for cancer are classified here.</p> <p><u>Products containing zopapogene imadenovac for recurrent respiratory papillomatosis (RRP) are classified here.</u></p> <p><u>Products containing nogapendekin alfa inbakicept for bladder cancer are classified here.</u></p>	r202 <del>65</del>

L4	<b>IMMUNOSUPPRESSANTS</b>	rR202 610
	<p><u>Immunosuppressants used to treat cancer are classified in the appropriate antineoplastic class. For example, nogapendekin alfa+inbakicept for bladder cancer is classified in L1X9</u></p>	
L4A	Out of use; can be reused from 2013.	D2010
L4B	<b>ANTI-TNF PRODUCTS</b>	r2020
	<p>Products containing anti-TNF substances are classified here, eg adalimumab, afelimomab, certolizumab pegol, etanercept, golimumab, infliximab. These products can be indicated for multiple conditions, eg rheumatoid arthritis, Crohn's disease, psoriasis.</p>	
	<p>Products containing apremilast for psoriatic conditions only are classified in D5B. Products containing apremilast for multiple conditions are classified in L4X.</p>	
L4C	<b>INTERLEUKIN INHIBITORS</b>	r20265
	<p><u>Includes products containing interleukin inhibitors, eg basiliximab, canakinumab, daclizumab, rilonacept.</u></p>	
	<p>Includes interleukin inhibitors indicated for the treatment of rejection in organ transplants (eg basiliximab, daclizumab etc) and for auto-inflammatory diseases such as CAPS (cryopyrin-associated periodic syndromes (eg canakinumab, rilonacept etc). Products containing daclizumab and indicated for multiple sclerosis (MS) only, or both MS and other conditions, are classified in N7A</p>	
	<p><u>Products containing levilimab for use in COVID-19 are classified here.</u></p>	
	<p><u>Products containing bimekizumab, brodalumab, ixekizumab, secukinumab or ustekinumab; for psoriatic skin conditions only are classified in D5B; for both psoriatic and also non-skin conditions, eg axial spondyloarthritis are classified here. Psoriatic arthritis is defined as a skin condition.</u></p>	
	<p><u>Products containing dupilumab for both atopic dermatitis and asthma are classified here. Products containing dupilumab for atopic dermatitis only are classified in D5X.</u></p>	
	<p>Products containing tocilizumab or anakinra and indicated for arthritic conditions only, or both arthritic and other conditions, are classified in M1C. Products containing tocilizumab or anakinra and indicated for arthritic and also other conditions are classified in M1C. Products containing brodalumab, ixekizumab, secukinumab or ustekinumab and indicated for skin conditions such as psoriasis and also other non-skin conditions, eg rheumatoid arthritis, are classified here. Psoriatic arthritis is defined as a skin condition.</p>	
	<p><u>Products containing daclizumab and indicated for use in kidney transplantation are classified here. Products containing daclizumab and indicated for multiple sclerosis and other conditions are classified in N7A.</u></p>	

Products containing interleukin inhibitors for asthma only, ~~are classified in R3M.~~ Products containing interleukin inhibitors for or for asthma and any of the following conditions, EGPA (eosinophilic granulomatosis with polyangiitis), chronic rhinosinusitis with nasal polypsis, nasal polyps, hypereosinophilic syndrome are classified in R3M.

~~Products containing dupilumab for atopic dermatitis are classified in D5X. Products containing dupilumab for both atopic dermatitis and asthma are classified here.~~

~~Products containing bimekizumab for psoriatic skin conditions only are classified in D5B. Products containing bimekizumab for both skin conditions and non-skin conditions, eg axial spondyloarthritis, ankylosing spondylitis etc, are classified here.~~

~~Products containing levilimab for use in COVID-19 are classified here~~

<b>L4D</b>	<p><b>JAK INHIBITORS</b></p> <p>Includes products containing JAK inhibitors, eg baricitinib, filgotinib, tofacitinib, upadacitinib, etc. These products are indicated for multiple conditions, eg rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, etc.</p> <p>Products containing JAK inhibitors primarily for cancer are classified in L1H7.</p> <p>Products containing JAK inhibitors are classified in A7 if only for gastro-intestinal conditions, in D5 if only for skin conditions (eg topical forms of ruxolitinib for atopic dermatitis), and in M1 if only for musculoskeletal conditions.</p>	I2024
<b>L4E</b>	<p><b><u>COMPLEMENT INHIBITORS</u></b></p> <p><u>Includes products containing complement inhibitors, eg eculizumab, iptacopan, pozelimab, ravulizumab, etc. These products are indicated for multiple conditions, eg atypical haemolytic uraemic syndrome (aHUS), CHAPLE disease, generalised myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD), paroxysmal nocturnal haemoglobinuria (PNH), etc.</u></p> <p><u>Products containing vilobelimab for use in COVID-19 are classified here.</u></p> <p><u>Products containing complement inhibitors: for haemolysis in cold agglutinin disease only are classified in B3X; for hereditary angioedema only are classified in B6D; for atypical haemolytic uraemic syndrome (aHUS) and/or paroxysmal nocturnal haemoglobinuria (PNH) only are classified in B6X; for vasculitic conditions only, eg granulomatosis with polyangiitis, are classified in C6X; for kidney conditions only, eg IgA nephropathy, are classified in G4X; for generalised myasthenia gravis (gMG) only are classified in M5X; for geographic atrophy only are classified in S1X.</u></p>	I2026
<b>L4F</b>	<p><b><u>CALCINEURIN INHIBITORS</u></b></p> <p><u>Includes products containing calcineurin inhibitors, eg ciclosporin, tacrolimus, etc. for the prevention and treatment of organ transplant rejection, graft versus host disease etc.</u></p> <p><u>Products containing calcineurin inhibitors are classified in D5 if only for skin conditions (eg topical forms of tacrolimus for atopic dermatitis), or in S1 if only for ophthalmological conditions. Products containing voclosporin are classified in G4X.</u></p>	I2026

L4X	<b>OTHER IMMUNOSUPPRESSANTS</b>	r202 <sup>65</sup>
	<p>Immunosuppressants used in the treatment of rejection in organ transplants are classified here, or in L4C if they contain interleukin inhibitors.</p>	
	<p><del>Includes eg azathioprine, cyclosporin, muromonab-ed3, mycophenolate mofetil, tacrolimus unless classified elsewhere because of a specific indication or formulation. For example, ophthalmic cyclosporin for dry eye is classified in S1K9 and dermatological tacrolimus is classified in D5X. Products containing antilymphocyte or antithymocyte immunoglobulins are classified here.</del></p>	
	<p><del>Products for multiple sclerosis are classified in N7A. Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified in N7A.</del></p>	
	<p><del>Products containing apremilast for psoriatic skin conditions only, are classified in D5B. Psoriatic arthritis is defined as a skin condition. Products containing apremilast for multiple conditions are classified here. multiple conditions are classified here. Products containing apremilast for psoriatic skin conditions only are classified in D5B. Psoriatic arthritis is defined as a skin condition.</del></p>	
	<p><del>Products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers are classified in L1K. Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified in L1K. Products containing thalidomide for erythema nodosum leprosum only are classified here.</del></p>	
	<p><del>Products containing thalidomide or its analogues for erythema nodosum leprosum (ENL) only are classified here, but for cancer, or for both cancer and ENL, are classified in L1K</del></p>	
	<p><del>Products containing leflunomide for multiple conditions are classified here. Products containing leflunomide but for rheumatoid arthritis only are classified in M1C.</del></p>	
	<p><del>Products containing complement inhibitors: for paroxysmal nocturnal haemoglobinuria (PNH) only are classified in B6X; for kidney conditions only, eg IgA nephropathy, are classified in G4X; for multiple conditions are classified here.</del></p>	
	<p><del>Products containing efgartigimod alfa for both myasthenia gravis and immune thrombocytopenia, or both myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP) are classified here. Products containing efgartigimod alfa multiple conditions are classified here, but for myasthenia gravis only are classified in M5X.</del></p>	
	<p><del>Products containing immunosuppressants and indicated for multiple sclerosis (MS) only, or both MS and other conditions are classified in N7A. Products containing pozolimab for complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) disease are classified here.</del></p>	
	<p><del>Products containing vilobelimab for use in COVID-19 are classified here.</del></p>	

Corticosteroids are not classified here.

M1C	<p><b>SPECIFIC ANTI-RHEUMATIC AGENTS</b></p> <p>This class includes abatacept, anakinra, tocilizumab, gold preparations, bucillamine, penicillamine and quinolines (eg oxycinchophen). Includes products containing mesalazine, olsalazine, <u>seniprutug</u> and sulphasalazine if specifically indicated for rheumatic conditions. Products containing aminosalicylates and used for intestinal inflammatory conditions, are classified in A7E1.</p> <p><u><b>Azathioprine is in L4X.</b></u> Products containing methotrexate for rheumatic conditions are classified here; otherwise, methotrexate is classified in <u><b>D or L14B or in D.</b></u></p> <p><u><b>Products containing interleukin inhibitors and only indicated for arthritic conditions are classified here. Products containing tocilizumab or anakinra and indicated for both arthritic and other conditions are classified here. Other interleukin inhibitors indicated for multiple conditions including arthritis are classified in L4C.</b></u></p> <p><u><b>Products containing anti-TNF substances are classified in L4B.</b></u></p> <p>Products containing baricitinib, filgotinib, tofacitinib or upadacitinib (JAK inhibitors), and indicated for <u><b>rheumatoid conditions arthritis</b></u> only, are classified here. Products containing baricitinib, filgotinib, tofacitinib or upadacitinib for multiple conditions are classified in L4D.</p> <p>Products containing leflunomide, and indicated for <u><b>rheumatoid conditions arthritis</b></u> only, are classified here. Products containing leflunomide for multiple conditions are classified in L4X.</p> <p><u><b>Products containing interleukin inhibitors and only indicated for arthritic conditions are classified here. Products containing tocilizumab or anakinra and indicated for both arthritic and other conditions are classified here. Other interleukin inhibitors indicated for multiple conditions including arthritis are classified in L4C.</b></u></p> <p><u><b>Products containing anti-TNF substances are classified in L4B.</b></u></p> <p><u><b>Products containing azathioprine are classified in L4X.</b></u></p> <p>Psoriatic arthritis is defined as a skin condition.</p>	r20264
-----	---	--------

<b>M5</b>	<b>OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM</b>	
<b>M5A</b>	Out of use; can be reused from 1996.	D1993
<b>M5B</b>	<b>BONE CALCIUM REGULATORS</b>  Calcitonin products are classified in H4A. Products containing calcium only are classified in A12A and fluoride products are classified in A12C2.	R2002
M5B1	Out of use; can be reused from 2010.	D2007
M5B2	Out of use; can be reused from 2010.	D2007
M5B3	<b>Bisphosphonates for osteoporosis and related disorders</b>  Includes products indicated and used mainly for osteoporosis and Paget's disease of bone, eg those containing alendronic acid, etidronic acid, ibandronic acid, risedronic acid, zoledronic acid, when indicated for these conditions. Combinations of bisphosphonates with calcium, calcitriol or colecalciferol are also classified here.	r2024
M5B4	<b>Bisphosphonates for tumour-related calcium disorders</b>  Includes products indicated and used mainly for tumour-related calcium disorders (eg hypercalcaemia of malignancy) eg those containing clodronic acid, etidronic acid, ibandronic acid, pamidronic acid, zoledronic acid when indicated for these conditions.	I2007
M5B9	<b>Other bone calcium regulators</b>  Includes other specific products which are used for osteoporosis (eg ipriflavone).  <u>Products containing denosumab for giant cell tumour of bone, with or without other indications related to bone loss (osteoporosis, malignancy-related bone loss etc.), are classified here.</u>	<u>rI2002</u> <u>6</u>

M5X	<b>ALL OTHER MUSCULOSKELETAL PRODUCTS</b>	r20265
	<p>Includes all other products for disorders of the musculoskeletal system not classified elsewhere. Includes musculoskeletal products containing substances such as cartilage extract, chondroitin, etc. Products containing chondroitin and glucosamine alone or in combination with other substances are classified here. Combinations of glucosamine with nonsteroidal anti-inflammatories are classified in M1A2. Topical glucosamine and chondroitin products are classified in M2A.</p> <p>Includes hydroquinine indicated for restless leg syndrome.</p> <p>Includes herbal products used for musculoskeletal pain.</p> <p><u>Products containing amifampridine for Lambert-Eaton myasthenic syndrome are classified here.</u></p> <p>Products containing burosumab for X-linked hypophosphataemia are classified here.</p> <p><u>Products containing nusinersen, onasemnogene abeparvovec or risdiplam for spinal muscle atrophy (SMA) are classified here.</u></p> <p><u>Products containing vamorolone for Duchenne muscular dystrophy (DMD) are classified here.</u></p> <p>Products containing mexiletine for non-dystrophic myotonic disorders are classified here; products containing mexiletine for cardiac arrhythmias are classified in C1B .</p> <p>Products containing diclofenamide for primary periodic paralysis are classified here. <del>Products containing diclofenamide for glaucoma are classified in S1E1.</del> Products containing diclofenamide for diuretic use are classified in C3A9. <u>Products containing diclofenamide for glaucoma are classified in S1E1.</u></p> <p><del>Products containing vamorolone for Duchenne muscular dystrophy (DMD) are classified here.</del></p> <p><del>Products containing amifampridine for Lambert-Eaton myasthenic syndrome are classified here.</del></p> <p><del>Products containing nusinersen, onasemnogene abeparvovec or risdiplam for spinal muscle atrophy (SMA) are classified here.</del></p> <p>Products containing efgartigimod alfa, <u>nipocalimab</u>, rozanolixizumab, or zilucoplan for myasthenia gravis only are classified here. Products containing efgartigimod alfa for both myasthenia gravis and immune thrombocytopenia, or both myasthenia gravis and chronic demyelinating immune polyneuropathy (CIDP) are classified in L4X.</p>	

<b>N3</b>	<b>ANTI-EPILEPTICS</b>	
<b>N3A</b>	<b>ANTI-EPILEPTICS</b>  Also includes products for non-epileptic convulsions, eg in pregnancy.  Products containing clonazepam are classified here.  Products containing gabapentinoids, eg gabapentin, pregabalin, etc, for epilepsy only, and for epilepsy and also other conditions are classified in N2D.	r2025

<b>N4</b>	<b>ANTI-PARKINSON DRUGS</b>	
<b>N4A</b>	<b>ANTI-PARKINSON DRUGS</b>  Products containing bromocriptine: for Parkinson's disease only are classified here: for diabetes mellitus only are classified in A10X9: for multiple conditions are classified in G2D: for acromegaly only are classified in H1C2. <i>In Japan, all bromocriptine products are classified here.</i>  Products containing ropinirole or similar substances for restless leg syndrome are classified here.	r202 <del>65</del>

<b>N5B6</b>	<b><u>Orexin Antagonists</u></b>	<b>I2026</b>
<b>N5C</b>	<p><u>Includes products containing orexin receptor antagonists, eg daridorexant, lemborexant, suvorexant etc. for insomnia.</u></p> <p><b>TRANQUILLISERS</b></p> <p>Includes minor tranquillisers, eg benzodiazepines, hydroxyzine, meprobamate, but excludes benzodiazepines indicated exclusively for the treatment of insomnia, eg nitrazepam, flurazepam (N5B1). Combinations with psychoanaleptics are classified in N6C. Products containing clonazepam are classified in N3A.</p>	R2004

<b>N7D</b>	<b>ANTI-ALZHEIMER PRODUCTS</b>	I1998
N7D1	<b>Anti-Alzheimer products, cholinesterase inhibitors</b>	R2003
	Includes eg donepezil, galantamine, rivastigmine and tacrine.	
N7D9	<b>All other anti-Alzheimer products</b>	I1998
	Includes all other products specifically used for Alzheimer's disease.	
<b>N7E</b>	<b>DRUGS USED IN ALCOHOL DEPENDENCE</b>	<u>rR200</u> <u>26</u>
	Includes acamprosate, calcium carbimide, disulfiram. Naltrexone when used in alcohol <u>use disorder (AUD)</u> or both <u>AUD and opioid use disorder (OUD)</u> <u>dependence</u> is classified here.	
<b>N7F</b>	<b>DRUGS USED IN OPIOID DEPENDENCE</b>	<u>rR200</u> <u>26</u>
	Includes naltrexone, except when <u>also</u> used in alcohol <u>dependence-use disorder</u> (use N7E).	
<b>N7X</b>	<b>ALL OTHER CNS DRUGS</b>	r202 <u>65</u>
	Includes parasympathetic agents. Benzodiazepine antagonists such as flumazenil are classified here. Atomoxetine is included in this class. Products containing gabapentinoids, eg. crisugabalin, gabapentin, gabapentin enacarbil, mirogabalin, pregabalin, etc, plain or in combination with other substances, are classified in N2D.	
	Products containing pilocarpine and indicated for both dry mouth and dry eye are classified here.	
	Products indicated for multiple sclerosis are classified in N7A. Products containing fampridine for improvement in walking in multiple sclerosis are classified here.	
	Products indicated for amyotrophic lateral sclerosis (ALS) are classified here.	
	Products containing tafamidis for transthyretin amyloid polyneuropathy (TAP) only are classified here. Products containing tafamidis for transthyretin amyloid cardiomyopathy (TAC) only are classified in C1X. Products containing tafamidis for both TAP and TAC are classified here.	
	Products containing inebilizumab or satralizumab for neuromyelitis optica spectrum disorder (NMOSD) <u>only</u> are classified here. <u>Product containing inebilizumab for multiple conditions are classified in L4X.</u>	
	Products containing naloxone for reversal of CNS depression in opioid overdose or intoxication are classified here.	

Products containing eladocagene exuparvovec for the treatment of human aromatic L-amino acid decarboxylase (AADC) are classified here.

<b>R7</b>	<b>OTHER RESPIRATORY SYSTEM PRODUCTS</b>	
<b>R7A</b>	<b>RESPIRATORY STIMULANTS</b>  Includes centrally acting respiratory stimulants such as lobeline, ethamivan, crotetiamide, crotopamide, nikethamide and doxapram (plain only).  Also includes products specifically indicated for primary apnoea in premature newborn babies.	R2006
<b>R7B</b>	<b>CYSTIC FIBROSIS PRODUCTS</b>  Products containing dornase alfa for cystic fibrosis are classified in R5C.	I2021
R7B1	<b>Cystic fibrosis transmembrane regulator (CFTR) modulators</b>  Includes products containing eg elexacaftor, ivacaftor, lumacaftor, tezacaftor, etc for cystic fibrosis.	I2021
<b>R7C</b>	<b>LUNG SURFACTANTS</b>  Includes substances such as colfoscaryl palmitate used in neonatal respiratory distress syndrome.	I1996
<b>R7D</b>	<b>IDIOPATHIC PULMONARY FIBROSIS PRODUCTS</b>  Includes products containing eg pirfenidone, nintedanib, etc for idiopathic pulmonary fibrosis.  <u>Products containing nerandomilast for idiopathic pulmonary fibrosis (IPF), and/or progressive pulmonary fibrosis (PPF), are classified here.</u>  Products containing nintedanib for idiopathic pulmonary fibrosis only are classified here. <del>Products containing nintedanib for cancer only are classified in L1H9.</del> Products containing nintedanib for both cancer and idiopathic pulmonary fibrosis are classified here. <u>Products containing nintedanib for cancer only are classified in L1H9.</u>	<u>rI2026</u> <u>4</u>
<b>R7X</b>	<b>ALL OTHER RESPIRATORY SYSTEM PRODUCTS</b>  Products containing inhaled sargramostim for autoimmune pulmonary alveolar proteinosis (aPAP) are classified in R7X.	r2025

<b>T</b>	<b>DIAGNOSTIC AGENTS</b>	I1994
<b>T1</b>	<b>DIAGNOSTIC IMAGING</b>	I1994
<b>T1A</b>	<b>LOW OSMOLAR ANGIO-UROGRAPHY</b>	I1994
<b>T1B</b>	<b>IONIC ANGIO-UROGRAPHY</b>	I1994
<b>T1C</b>	<b>GASTROENTEROGRAPHY</b>	<u>r2026I</u> <u>1994</u>
	<u>Products containing pronase for use as a premedication in endoscopy are classified here.</u>	
<b>T1D</b>	<b>CHOLECYSTOGRAPHY AND CHOLANGIOGRAPHY</b>	I1994
<b>T1E</b>	<b>MRI AGENTS</b>	I1994
	Magnetic resonance imaging agents.	
<b>T1F</b>	<b>ULTRASOUND AGENTS</b>	I1994
<b>T1G</b>	<b>RADIODIAGNOSTIC AGENTS</b>	I2003
	Includes radiopharmaceutical products used in diagnosis. Radiopharmaceuticals used as therapeutic agents are classified in V3C.	
<b>T1X</b>	<b>OTHER IMAGING AGENTS</b>	<u>r2026I</u> <u>8</u>
	Products containing aminolaevulinic acid for cancer therapy are classified in L1X8.	
	<u>Products containing pegulicianine for fluorescence imaging during cancer surgery are classified here.</u>	